The immune checkpoint inhibitors market has been one of the most dynamic segments in the biopharmaceutical industry over the past decade, reflecting significant advancements in cancer treatment. These therapies, which enhance the immune system's ability to fight cancer by inhibiting proteins that suppress immune responses, have gained traction for their effectiveness across various cancer types. Here’s a detailed overview of the immune checkpoint inhibitors market, including its size, growth drivers, regional insights, competitive landscape, and future trends.